MedTrace Logo

Patient-Centered Collaborative Care for Preventing Post-Traumatic Stress Disorder After Traumatic Injury

NCT00270959 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 207

Last updated 2020-11-04

No results posted yet for this study

Summary

This study will evaluate the effectiveness of patient-centered collaborative care that combines behavioral therapy and drug therapy as compared to usual care in reducing symptoms of post-traumatic stress disorder in people who have survived a traumatic injury.

Conditions

  • Post-Traumatic Stress Disorder

Interventions

BEHAVIORAL

Cognitive Behavioral Therapy

Behavioral therapy includes standard cognitive behavioral therapy, with an emphasis on behavioral activation. Treatment is administered on the basis of the participants' individual needs and may continue for up to 12 months.

BEHAVIORAL

Motivational Interviewing

Motivational interviewing is designed to address alcohol and drug use.

DRUG

FDA-Approved Anti-Anxiety Medications

Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.

BEHAVIORAL

Standard Care Control

Standard care control includes the usual treatment for injured trauma survivors.

Sponsors & Collaborators

Principal Investigators

  • Douglas F. Zatzick, MD · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2010-09-30
Completion
2013-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00270959 on ClinicalTrials.gov